Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
RN

NASDAQ · RNTX

Rein Therapeutics Inc.

Healthcare · Medical - Pharmaceuticals

$0.67

Up+$0.03 (+5.05%)

Updated Nov 4, 2026, 9:34 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
40.22M
P/E ratio
-0.68
Dividend yield
0.00%
52-week range
$0.54 – $2.10
Volume
256.62K
Avg. volume
960.39K

Price performance · RNTX

RNTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

RNTX closed at $0.67 after 21 trading sessions, down 19.09% for the selected period.

Last close
$0.67
Period change
-19.09%
Period low
$0.55
Period high
$0.83
Daily close
View OHLC price history
RNTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.668$0.705$0.6341$0.6675256.62K
Nov 2, 2026$0.6898$0.7114$0.62$0.6354392.74K
Oct 30, 2026$0.70$0.70$0.66$0.67121.46K
Oct 29, 2026$0.7074$0.7495$0.6766$0.7266189.14K
Oct 28, 2026$0.697$0.7409$0.6601$0.7147389.89K
Oct 27, 2026$0.60$0.7199$0.5901$0.7042622.14K
Oct 26, 2026$0.57$0.6085$0.56$0.5832394.14K
Oct 23, 2026$0.595$0.6116$0.5718$0.5821331.33K
Oct 22, 2026$0.62$0.6244$0.59$0.6024305.25K
Oct 21, 2026$0.607$0.65$0.5951$0.6248266.09K
Oct 20, 2026$0.545$0.6073$0.5432$0.5951296.44K
Oct 19, 2026$0.5798$0.615$0.5515$0.552502.15K
Oct 16, 2026$0.613$0.6219$0.5699$0.5903372.1K
Oct 15, 2026$0.60$0.666$0.551$0.6281.37M
Oct 14, 2026$0.7546$0.755$0.5401$0.5861.15M
Oct 13, 2026$0.7774$0.7774$0.7502$0.7546142.81K
Oct 12, 2026$0.77$0.7877$0.75$0.7849108.13K
Oct 9, 2026$0.7607$0.81$0.7607$0.794307.54K
Oct 8, 2026$0.784$0.784$0.7461$0.7693477.62K
Oct 7, 2026$0.80$0.8169$0.7802$0.7887446.97K
Oct 6, 2026$0.825$0.8341$0.8085$0.825185.63K

Latest RNTX news

The latest Smart Investors Daily articles mentioning RNTX.

Stock researchCompany · Overview

RNTX research

Overview

Company profile and research snapshot.

Company profile

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
RNTX recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Jul 20, 2026Maxim GroupBuy—
Jun 1, 2026HC Wainwright & Co.Buy—
Jan 21, 2026Brookline CapitalHold—
Sep 22, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Poster Presentation Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation s

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By